Best Life Sciences Platforms and Tools Companies in Spain
The 136 best Life Sciences Platforms and Tools companies in Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: SOM Biotech.
Spain's Life Sciences Platforms and Tools sector has 136 companies on our radar, with $118M in total disclosed funding and not a single unicorn yet. Som Biotech leads the pack at $29M raised, followed by Sequentia Biotech at $11M, and the rest of the field is clustered well below that. The funding gap between the top two and everyone else tells you something: capital here is still selective, still concentrated, and the breakout moment for the broader cohort hasn't arrived.
But the global backdrop makes that gap worth watching. The worldwide market sat at $89.4B in 2020 and is forecast to reach $183.8B by 2027, a 10.8% CAGR according to ResearchAndMarkets.com, driven by advances in mass spectrometry resolution, quantitative accuracy, and information sciences. Regulatory hurdles remain a real friction point for Spanish players trying to scale beyond domestic clinical and research networks. I'd note that the most active investors here, Europa, EIC Fund, and Caixa Capital Risc, are patient, public-leaning backers, which shapes the pace. So if you're mapping this space for partnership or deal flow, the opportunity is real but the timeline is European, not Silicon Valley.
- Precedence Research
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Spain
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SOM Biotech Developer of platform for screening compounds to treat rare diseases | $29M | 30 mo ago | Series B | 15 | Raul Insa Founder & CEO | — | 117 patents Pharmaceutical compounds and formulations for treating dystrophinopathies, movement disorders, and PKU | — |
| 2 | Algenex Developer of recombinant biologics for animal and human health | $13M | 69 mo ago | Series B | 28 | — | Top 50M | 3 patents Rabbit hemorrhagic disease vaccines for veterinary immunization | — |
| 3 | Sequentia biotech Bioinformatics technologies and sevices | $11M | 20 mo ago | Series A | 23 | — | Top 10M | — | — |
| 4 | AlphaSIP Nanotube-based biosensor chip for diagnostic applications | $8M | 94 mo ago | Funding Raised | — | Brent Segal Co-Founder | — | — | — |
| 5 | EBERS Medical 3D cell culture bioreactors and culture chambers for tissue engineering research | $7M | 66 mo ago | Funding Raised | — | Pedro Moreo Co-Founder & CEO | — | 20 patents Ex vivo organ perfusion systems for normothermic preservation of liver and kidney | — |
| 6 | A4Cell Developer of tool for monitoring and studying alive single cell | $5M | 31 mo ago | Series B | 14 | Elena Rivas CEO | Top 50M | — | — |
| 7 | Ikan Biotech Provider of preclinical in vivo drug screening assays using Zebra Fish models | $5M | 105 mo ago | Deadpooled | 12 | Roberto Diez Co-Founder & CEO | — | — | — |
| 8 | Transplant Biomedicals Organ transport devices | $4M | 113 mo ago | Series A | — | — | — | — | — |
| 9 | Raman Health Technologies Developer of a diagnostics platform for the diagnosis of neurodegenerative diseases | $4M | 127 mo ago | Deadpooled | — | Carlo Zanotti CEO | — | 7 patents Early detection of Alzheimer's via biomarker analysis using sample holders. | — |
| 10 | Histocell Provider of products and services in cell therapy for regenerative medicine | $3M | 72 mo ago | Series A | 24 | — | Top 50M | 110 patents Regenerative biomaterial scaffolds and antioxidant hydrogel dressings for oral and skin wound healing | — |
| 11 | Atlas Molecular Pharma Develops proprietary drug discovery platform | $3M | 53 mo ago | Series A | 6 | Enrique Castellon CEO & President | — | 10 patents Oral ciclopirox formulations and uroporphyrin-based therapies for prion diseases | — |
| 12 | Medibiofarma Developer of drugs for treating cancer | $3M | 26 mo ago | Seed | 8 | Rodolfo Rodriguez Iglesias Founder | — | 60 patents Small-molecule modulators of PGE2 receptors, PPAR‑γ agonists, and HDAC1/2 inhibitors | — |
| 13 | microLIQUID Specializes in microfluidics | $2M | 57 mo ago | Acquired | 60 | Borja Barredo Founder & CEO | — | 16 patents Microfluidic sealing structures and monolithic normally‑closed valves for lab‑on‑a‑chip devices | — |
| 14 | Flomics Provider of liquid biopsy-based diagnostics services | $2M | 27 mo ago | Seed | 19 | Joao Curado CEO | Top 50M | — | — |
| 15 | Zebrafish Lab Zebrafish based services for preclinical and environmental applications | $2M | 81 mo ago | Funding Raised | — | Roberto Diez-Martinez Co-Founder & CEO | — | — | — |
| 16 | Ingeniatrics Provider of microencapsulation services for new forms of aerosols, emulsions, and microparticles | $2M | 131 mo ago | Seed | 6 | — | — | — | 1 launch |
| 17 | ZYMVOL Provider of enzyme engineering services using computational and AI-driven molecular modeling | $1M | 15 mo ago | Seed | 28 | Maria Lucas Co-Founder & CEO | Top 10M | — | 1 launch |
| 18 | Sepmag Developer of bio-magnetic separation systems | $1M | 207 mo ago | Seed | 6 | Lluis M Martinez Founder & CSO | — | — | — |
| 19 | Regemat 3D Developer of 3D bioprinting and regenerative medicine | $1M | 41 mo ago | Seed | 22 | — | Top 10M | 3 patents 3D bioprinting and engineered tissue fabrication for regenerative medicine | — |
| 20 | Genomcore Provider of a platform for personal genomic analysis | $985K | 18 mo ago | Series A | — | Miquel Angel Bru Co-Founder | Top 50M | 4 patents Secure data access control for wireless communication networks | — |
| 21 | Immunostep Diagnostics and clinical research reagents by flow cytometry | $800K | 154 mo ago | Late Stage | 14 | Ricardo Jara Acevedo CEO | Top 10M | 12 patents High-throughput assays for extracellular vesicle quantification and one-step phagocytosis/activation/death detection | — |
| 22 | BiOD Developer of In-Vitro Diagnostic (IVD) platform using optical interrogation of Biochip-KITs | $798K | 104 mo ago | Deadpooled | — | Francisco Gutierrez Co-Founder | — | — | — |
| 23 | NeoCodex Provider of designs and implements genetic markers/biomarkers for various diseases | $785K | 242 mo ago | Deadpooled | — | Enrique Vazquez Tatay Co-Founder | — | 14 patents Patents concentrated in computing, sensing & instrumentation | — |
| 24 | BioQuoChem Developer of kits and electrochemical devices for the measurement of redox parameters | $733K | 43 mo ago | Series A | 12 | Henar Muñoz Cimadevilla CEO | Top 10M | 17 patents Analytical instrumentation for selective hydrogen peroxide‑based oxidation measurements in complex samples | 1 launch |
| 25 | Era7 Bioinformatics Provider of services in Next Generation Sequencing (NGS) and Bioinformatics services | $631K | 101 mo ago | Series A | — | — | — | — | — |
| 26 | Innoprot Provider of products and services in drug discovery | $628K | 74 mo ago | Funding Raised | 14 | Jorge Gamiz Founder & CEO | Top 5M | — | — |
| 27 | Beonchip Developer of organ-on-chip devices for life science research purposes | $466K | 85 mo ago | Funding Raised | — | Luis Fernandez Co-Founder | Top 10M | — | 1 launch |
| 28 | Biotechvana Software solutions and services for bio-informatics | $451K | 123 mo ago | Funding Raised | — | Carlos Llorens CEO | Top 50M | — | — |
| 29 | Biobide CRO specializing in Zebrafish toxicity and efficacy assays | $432K | 33 mo ago | Funding Raised | 17 | Andoni Cruz Co-Founder | — | — | — |
| 30 | Biopolis Fermentation service provider for the agri-food, pharmaceutical, chemical, and energy industries | $330K | 60 mo ago | Acquired | 28 | — | — | 184 patents Probiotic and postbiotic therapeutics for dermatology, fertility, and gut health | — |
| 31 | Pangaea Biotech Provider of drug development and molecular diagnostics services on cancer treatment | $298K | 101 mo ago | Public | 55 | — | Top 10M | 104 patents Molecular diagnostics and targeted oncology therapeutics using nucleic acid isolation and luminescent assays | 1 award |
| 32 | Qgenomics Provider of genomic research and diagnostics services for research purposes | $297K | 59 mo ago | Funding Raised | — | Lluis Armengol CEO and Scientific Director | Top 10M | — | — |
| 33 | OSASEN Developing and offering an amperometric enzymatic biosensors | $284K | 77 mo ago | Seed | — | Asier Albizu CEO | — | — | — |
| 34 | Leadartis Provider of protein engineering platform for multi-target therapeutic development | $242K | 73 mo ago | Seed | 6 | — | — | 25 patents Engineered trimeric antibody‑collagen fusion proteins for cancer immunotherapy | — |
| 35 | Paperdrop Diagnostics Provider of rapid diagnostics tests for ageing issue based on lateral flow immunoassays | $210K | 67 mo ago | Funding Raised | — | Angel Alonso Co-Founder & CFO | — | 4 patents Multiplexed nucleic acid detection and nanoparticle-enhanced lateral flow diagnostic assays | — |
| 36 | Biomedal Develops and markets products for bioprocess industry and diagnostics | $183K | 53 mo ago | Funding Raised | 32 | — | Top 50M | 47 patents Non‑invasive diagnostic assays for intestinal permeability and gluten peptide detection in bodily fluids. | — |
| 37 | Laboratorio CIFGA Manufacturer of reference material for biotoxins | $126K | 88 mo ago | Funding Raised | — | Manuel Lolo A CEO | Top 50M | — | 1 launch |
| 38 | HAWK Biosystems Developer of clinical assays for quantifying novel biomarkers | $123K | 48 mo ago | Seed | 14 | Fernando Aguirre CEO | Top 50M | — | — |
| 39 | Oxoprobics Biosciences Provider of microplate readers for research applications | $115K | 89 mo ago | Funding Raised | — | Juan Martin Co-Founder & CEO | — | — | — |
| 40 | Canvax Biotech Spanish biotech company with 3 businesses - drug discovery, biosensors and R&D tools | $111K | 127 mo ago | Funding Raised | — | Jose Huertas Jimenez Co-Founder | Top 5M | 34 patents Patents concentrated in health & consumer products | 1 launch |
| 41 | StemTek Therapeutics Stem cell focused research services for drug development for cancer treatment | $108K | 109 mo ago | Deadpooled | — | Angel Garcia Martin Co-Founder & CEO | — | 4 patents 3D culture techniques for generating cancer stem cell spheroids | — |
Top 12 Life Sciences Platforms and Tools companies in Spain
#1
Series A · Barcelona, Catalonia · founded 2013 · 23 employees$11.2Mraised▾
Sequentia Biotech offers services and technologies in the field of bioinformatics. Work is organised into four specialised divisions: Sequentia Green, Sequentia Health, Sequentia Research, and Sequentia Training. The offerings include bioinformatics services, NGS services along with software for data analysis. It also has custom databses such as database for Plant resistance gene database PRGdb, Variation DB etc.
- Sep 2024Series A$11.2M
- Sep 2022Grant (prize money)$2.1M
- 2021Grant (prize money)$61.3K
- Apr 2021Grant (prize money)$86.6K
#2
Seed · Barcelona, Catalonia · founded 2017 · 28 employees$1.4Mraised▾
Provider of enzyme engineering services using computational and AI-driven molecular modeling. The company offers enzyme optimization and discovery to help industries implement sustainable chemistry. They utilize an AI-Physics Hybrid approach to provide molecular-level insight, reduce development time, and accelerate enzyme evolution. The company supports research and development across diverse industries.
- Feb 2025Seed$3.1M
- Jan 2024Conventional Debt$762.6K
- Feb 2023Seed$1.4M
- Mar 2022Grant (prize money)$55.7K
#3
Series A · Esplugues De Llobregat, Catalonia · founded 2015$984.7Kraised▾
Provider of a platform for personal genomic analysis. The company provides DNA sequencing services and computing services for genomic analysis. Users can obtain, analyze and manage their complete genomic sequence from the company's cloud platform.
- Dec 2024Series A$5.3M
- Oct 2022Seed$984.7K
- Jun 2018Grant (prize money)$58.2K
- Jan 2018Grant (prize money)$60.1K
#4
Series B · Barcelona, Catalonia · founded 2009 · 15 employees$28.5Mraised▾
SOM Biotech is developing therapies for rare diseases. The company has developed a proprietary ligand-based in-silico platform for virtual compound screening. The company has developed a drug pipeline that includes SOM0226 for the treatment of TTR amyloidosis (phase II) and SOM3355 for the treatment of Huntington's disease (phase II). The other products in the pipeline include compounds for the treatments for cystic fibrosis, glioblastoma, and Alzheimer's disease.
- Dec 2023Series B$18.5M
- Mar 2019Series A$7.9M
- Jan 2017Seed$2.1M
#5
Seed · Noain, Navarre · founded 2016 · 8 employees$3.3Mraised▾
Medibiofarma is developing drugs for the treatment of cancer and neurodegenerative diseases. The company is developing drugs that target the proteins that activate the immune system through computational drug design, chemoinformatics, and in vitro pharmacology studies.
- Apr 2024Seed$1.1M
- Apr 2019Seed$2.2M
#6
Series B · Madrid, Community of Madrid · founded 2018 · 14 employees$5.4Mraised▾
Developer of tool for monitoring and studying alive single cell. The SPAchip Technology is used to study alive cell behavior, physiology, and information of cells. It is also used to analyze interactions among biomolecules and monitor individual cell responses over time.
- Nov 2023Series B$3.3M
- Apr 2022Grant (prize money)$747.2K
- Dec 2021Series A$1.4M
- Apr 2019Seed$728.7K
#7
Seed · Barcelona, Catalonia · founded 2018 · 19 employees$2.3Mraised▾
Provider of liquid biopsy-based diagnostics services. The company offers a tailored sequencing workflow for RNA-based diagnostics using RNA liquid biopsy tests. It uses the Blood sample to obtain sequencing data to create liquid biopsies to enable the diagnosis of the patients.
- Mar 2024Seed$1.2M
- Mar 2022Seed$1.1M
#8
Funding Raised · Seville, Andalusia · founded 2022$55.1Kraised▾
Developer of agitation systems for bio-fermentation reactors. It offers system that reduces the damage to cells and optimizes mixing in the vessel for development of vaccines and cultures.
- Sep 2024Grant (prize money)$55.1K
- Oct 2023Grant (prize money)—
#9
Series B · Madrid, Community of Madrid · founded 2005 · 28 employees$13.3Mraised▾
Developer of recombinant biologics for animal and human health. It has developed platforms within a baculovirus expression vector system that includes Top-Bac, a proprietary expression cassette which helps to improve the quality of proteins produced and IBES which is based on the use of insect larvae as disposable, living bioreactors. It claims that the proteins produced can be used to develop vaccines, diagnostic reagents, and therapeutic molecules.
- Sep 2020Series B$8.8M
- Mar 2019Series A$4.5M
#10
Funding Raised · Zaragoza, Aragon · founded 2009$6.8Mraised▾
EBERS Medical develops 3D cell culture bioreactors and culture chambers for tissue engineering. It has a range of flow bioreactors that can be used to mimic in vivo condition when combined with the right scaffold and flow conditions. It has three types of scaffolds, that are marketed on behalf of Bio-byblos, a Taiwanese company. In addition, the company also has a series of organs-on-a-chip that use advanced microfluidics.
- Nov 2020Grant (prize money)$3.1M
- Jan 2020Grant (prize money)$627.6K
- Jun 2018Grant (prize money)$3M
- Oct 2016Grant (prize money)$54.9K
#11
Seed · Granada, Andalusia · founded 2015 · 22 employees$1.1Mraised▾
Developer of 3D bioprinting and regenerative medicine. The company uses 3D printing technologies for regenerative therapies. Bioprinter is a device that can manufacture 3D parts with a customized external structure and a meshed internal structure from different materials, seeded with cells. The first version of the bioprinter is focused to treat cartilage degeneration and degenerative joint diseases. Bioprinted 3D structures can also be used for drug development.
- Jan 2023Grant (prize money)$196.6K
- May 2022Seed$554.9K
- Oct 2020Seed$580.3K
- Jan 2020Grant (prize money)$281.5K
#12
Series A · Derio, Basque Country · founded 2015 · 6 employees$3.4Mraised▾
Atlas Molecular Pharma engages in developing drug discovery platform called CHASSYS. The technology is an integrated platform to develop new chemical entities and repurposed drugs. It is currently working on Congenital Erythropoietic Porphyria wherein the autosomal recessive deficiency in the uroporphyrinogen III synthase (UROIIIS) enzyme causes build up of porphyrins in high concentration. Additionally, the company is also working on Prion Disease: and Tyrosianemia along with other diseases.
- Jan 2022Series A$3.4M
- Mar 2021Grant (prize money)$302.1K
- 2016Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Spain
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,742 Spain-affiliated papers.
- Universidad Internacional De La Rioja177
- European Molecular Biology Laboratory87
- Instituto de Salud Carlos III70
- Universitat Pompeu Fabra52
- Universitat de Barcelona51
- Genome8→51
- Transcriptome2→44
- Gene10→51
- Epigenetics2→18
- Chromatin1→16
- Gene2→46
- Clinical trial1→18
- Cancer2→17
- Genome4→17
- Breast cancer1→14
- Disease1→36
- Precision medicine1→11
- Gene1→7
- Phenotype1→7
- Metagenomics1→5
Where bioinformatics is researched across Spain
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.